Share Price and Basic Stock Data
Last Updated: December 9, 2025, 8:11 pm
| PEG Ratio | -10.75 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biocon Ltd, a prominent player in the pharmaceuticals industry, has shown a remarkable growth trajectory in recent years. The company’s revenue for the fiscal year ending March 2023 stood at ₹11,174 Cr, a significant increase from ₹8,184 Cr in FY 2022. This upward trend continued into FY 2024, with reported sales of ₹14,756 Cr. The latest quarterly figures show a healthy performance, with revenue reaching ₹3,954 Cr in December 2023, demonstrating resilience despite market fluctuations. The company’s ability to consistently increase sales—evident from the jump from ₹2,140 Cr in June 2022 to ₹3,774 Cr in March 2023—highlights its strong market position and effective operational strategies. However, this growth must be assessed against the backdrop of rising competition in the biopharmaceutical sector, which could impact future revenue streams.
Profitability and Efficiency Metrics
When delving into Biocon’s profitability, the figures present a mixed picture. The operating profit margin (OPM) has hovered around 22% for FY 2023 and FY 2024, indicating a stable but not exceptional efficiency in translating revenues into profits. The company’s net profit for FY 2024 was reported at ₹1,298 Cr, a significant recovery from ₹643 Cr in FY 2023. However, the return on equity (ROE) remains relatively low at 4.76%, suggesting that while Biocon is generating profits, it is not leveraging its equity as effectively as one might hope. Additionally, the interest coverage ratio (ICR) of 4.87x indicates that the company has a comfortable buffer to meet its interest obligations, yet the high P/E ratio of 108 raises questions about whether the stock is overvalued given its current profitability metrics.
Balance Sheet Strength and Financial Ratios
Biocon’s balance sheet presents a complex narrative. On one hand, the company’s reserves have grown to ₹26,135 Cr, reflecting a robust accumulation of retained earnings over the years. However, the total borrowings stood at ₹16,536 Cr, which raises concerns about financial leverage. The debt-to-equity ratio of 0.82 suggests that while Biocon is not excessively leveraged, it is operating with a significant amount of debt relative to its equity. The cash conversion cycle (CCC) of 18 days indicates that the company manages its working capital efficiently, but the rising debtor days at 131 in FY 2025 could reflect potential issues in receivables collection. Investors should keep an eye on how Biocon balances its growth aspirations with prudent financial management.
Shareholding Pattern and Investor Confidence
The shareholding structure of Biocon Ltd reveals interesting insights into investor confidence. Promoters hold 54.45% of the equity, a slight decline from earlier levels, which may suggest a gradual dilution of control. Meanwhile, domestic institutional investors (DIIs) have increased their stake to 22.06%, indicating growing confidence among local investors. Conversely, foreign institutional investors (FIIs) have reduced their holdings to 6.61%. This mixed sentiment may reflect concerns over valuation and growth prospects. The total number of shareholders has seen a steady increase, reaching 4,13,191, which could imply that retail interest remains robust despite the fluctuations in institutional ownership. This diverse ownership base can act as a stabilizing factor for the stock.
Outlook, Risks, and Final Insight
Looking ahead, Biocon faces a dual-edged sword of opportunities and risks. The growth in sales and increasing reserves position the company favorably in a competitive market. However, the high P/E ratio suggests that investors are pricing in aggressive growth expectations, which may not materialize if market conditions change. Additionally, the company’s profitability metrics, particularly the low ROE, underscore a need for strategic initiatives to enhance returns. Risks such as regulatory changes, competition from generics, and the impact of global economic conditions on demand for biopharmaceuticals could pose challenges. For investors, the key will be to weigh the potential for growth against these risks, considering whether Biocon’s current valuation reflects a fair assessment of its long-term prospects. As always, a careful analysis of the company’s ability to navigate these challenges will be crucial for making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biocon Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 32.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,214 Cr. | 384 | 479/192 | 87.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.7 Cr. | 29.8 | 30.5/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.60 Cr | 1,156.92 | 52.10 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,140 | 2,320 | 2,941 | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 |
| Expenses | 1,783 | 1,877 | 2,352 | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,193 |
| Operating Profit | 356 | 442 | 589 | 957 | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 749 |
| OPM % | 17% | 19% | 20% | 25% | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% |
| Other Income | 78 | 48 | -193 | 152 | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 80 |
| Interest | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 |
| Depreciation | 218 | 231 | 301 | 364 | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 |
| Profit before tax | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 |
| Tax % | 15% | 64% | -19% | 17% | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% |
| Net Profit | 167 | 82 | -21 | 414 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 |
| EPS in Rs | 1.20 | 0.39 | -0.35 | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 |
Last Updated: August 20, 2025, 12:45 pm
Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,942.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,417.00 Cr. (Mar 2025) to 3,942.00 Cr., marking a decrease of 475.00 Cr..
- For Expenses, as of Jun 2025, the value is 3,193.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,339.00 Cr. (Mar 2025) to 3,193.00 Cr., marking a decrease of 146.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 749.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,078.00 Cr. (Mar 2025) to 749.00 Cr., marking a decrease of 329.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 19.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 80.00 Cr., marking an increase of 23.00 Cr..
- For Interest, as of Jun 2025, the value is 277.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 212.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 65.00 Cr..
- For Depreciation, as of Jun 2025, the value is 455.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 455.00 Cr., marking an increase of 19.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 97.00 Cr.. The value appears to be declining and may need further review. It has decreased from 487.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 390.00 Cr..
- For Tax %, as of Jun 2025, the value is 8.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Mar 2025) to 8.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 459.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 370.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 2.87 (Mar 2025) to 0.23, marking a decrease of 2.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,367 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 15,771 |
| Expenses | 2,190 | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,792 | 5,562 | 6,391 | 8,762 | 11,540 | 12,008 | 12,506 |
| Operating Profit | 687 | 696 | 390 | 980 | 829 | 1,394 | 1,575 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,264 |
| OPM % | 24% | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 21% | 21% |
| Other Income | 56 | 158 | 639 | 173 | 228 | 340 | 228 | 260 | 72 | 18 | 853 | 1,217 | 248 |
| Interest | 2 | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 938 |
| Depreciation | 204 | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,737 |
| Profit before tax | 538 | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 838 |
| Tax % | 20% | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% | 15% | 24% | |
| Net Profit | 431 | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 657 |
| EPS in Rs | 3.45 | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 8.44 | 3.18 |
| Dividend Payout % | 24% | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.51% | 15.34% | 12.97% | -34.16% | 121.41% | -13.16% | -2.87% | -8.75% | -16.71% | 101.87% | 10.09% |
| Change in YoY Net Profit Growth (%) | 0.00% | -7.16% | -2.37% | -47.13% | 155.57% | -134.57% | 10.29% | -5.88% | -7.96% | 118.58% | -91.77% |
Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 23% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | -77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -3% |
| 3 Years: | 7% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 668 |
| Reserves | 2,927 | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 26,135 |
| Borrowings | 864 | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 18,362 | 16,536 |
| Other Liabilities | 1,860 | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 18,534 | 19,421 |
| Total Liabilities | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
| Fixed Assets | 1,525 | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 37,262 |
| CWIP | 1,206 | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 | 4,651 |
| Investments | 765 | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 2,333 |
| Other Assets | 2,255 | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,941 | 18,513 |
| Total Assets | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 600.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 68.00 Cr..
- For Reserves, as of Sep 2025, the value is 26,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,044.00 Cr. (Mar 2025) to 26,135.00 Cr., marking an increase of 5,091.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16,536.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 18,362.00 Cr. (Mar 2025) to 16,536.00 Cr., marking a decrease of 1,826.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 19,421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18,534.00 Cr. (Mar 2025) to 19,421.00 Cr., marking an increase of 887.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62,760.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 37,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 31,963.00 Cr. (Mar 2025) to 37,262.00 Cr., marking an increase of 5,299.00 Cr..
- For CWIP, as of Sep 2025, the value is 4,651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,508.00 Cr. (Mar 2025) to 4,651.00 Cr., marking a decrease of 3,857.00 Cr..
- For Investments, as of Sep 2025, the value is 2,333.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,127.00 Cr. (Mar 2025) to 2,333.00 Cr., marking an increase of 1,206.00 Cr..
- For Other Assets, as of Sep 2025, the value is 18,513.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,941.00 Cr. (Mar 2025) to 18,513.00 Cr., marking an increase of 1,572.00 Cr..
- For Total Assets, as of Sep 2025, the value is 62,760.00 Cr.. The value appears strong and on an upward trend. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
Notably, the Reserves (26,135.00 Cr.) exceed the Borrowings (16,536.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -177.00 | 695.00 | 388.00 | 978.00 | 827.00 | -1.00 | -1.00 | -3.00 | -4.00 | -16.00 | -13.00 | -15.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 91 | 78 | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 | 131 |
| Inventory Days | 116 | 132 | 153 | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 | 346 |
| Days Payable | 107 | 125 | 172 | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 | 460 |
| Cash Conversion Cycle | 85 | 98 | 59 | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 | 18 |
| Working Capital Days | -31 | -19 | -12 | 24 | 6 | -2 | -31 | 8 | 71 | 3 | -68 | -63 |
| ROCE % | 15% | 12% | 9% | 12% | 8% | 13% | 12% | 10% | 9% | 6% | 6% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 28,807,465 | 2.18 | 1071.93 | 16,770,774 | 2025-12-08 00:57:08 | 71.77% |
| SBI Midcap Fund | 13,969,697 | 2.26 | 519.81 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 13,000,000 | 1.64 | 483.73 | N/A | N/A | N/A |
| SBI Balanced Advantage Fund | 10,021,205 | 0.97 | 372.89 | 10,021,205 | 2025-04-22 17:25:40 | 0% |
| Nippon India Multi Cap Fund | 9,326,895 | 0.7 | 347.05 | N/A | N/A | N/A |
| Nippon India Focused Fund | 7,299,915 | 3.12 | 271.63 | N/A | N/A | N/A |
| Franklin India Mid Cap Fund | 5,862,280 | 1.71 | 218.14 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 5,680,217 | 3.28 | 211.36 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 4,792,542 | 0.98 | 178.33 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 4,719,374 | 2.1 | 175.61 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.46 | 8.55 | 3.88 | 5.44 | 6.24 |
| Diluted EPS (Rs.) | 8.46 | 8.54 | 3.87 | 5.42 | 6.19 |
| Cash EPS (Rs.) | 25.96 | 24.58 | 16.02 | 14.93 | 13.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 180.27 | 210.51 | 187.31 | 78.87 | 70.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 180.28 | 210.52 | 187.31 | 78.88 | 70.10 |
| Revenue From Operations / Share (Rs.) | 127.12 | 122.90 | 93.07 | 68.17 | 59.22 |
| PBDIT / Share (Rs.) | 36.44 | 34.68 | 24.05 | 18.18 | 15.89 |
| PBIT / Share (Rs.) | 22.38 | 21.62 | 14.78 | 11.40 | 9.93 |
| PBT / Share (Rs.) | 15.71 | 13.40 | 8.86 | 9.91 | 9.56 |
| Net Profit / Share (Rs.) | 11.91 | 11.51 | 6.75 | 8.15 | 7.63 |
| NP After MI And SOA / Share (Rs.) | 8.44 | 8.52 | 3.85 | 5.40 | 6.17 |
| PBDIT Margin (%) | 28.66 | 28.22 | 25.84 | 26.67 | 26.83 |
| PBIT Margin (%) | 17.60 | 17.58 | 15.88 | 16.72 | 16.77 |
| PBT Margin (%) | 12.36 | 10.90 | 9.52 | 14.54 | 16.14 |
| Net Profit Margin (%) | 9.36 | 9.36 | 7.24 | 11.95 | 12.88 |
| NP After MI And SOA Margin (%) | 6.63 | 6.92 | 4.14 | 7.92 | 10.42 |
| Return on Networth / Equity (%) | 4.68 | 5.16 | 2.58 | 7.69 | 9.83 |
| Return on Capital Employeed (%) | 6.04 | 6.37 | 4.07 | 8.26 | 8.32 |
| Return On Assets (%) | 1.72 | 1.82 | 0.88 | 3.17 | 3.99 |
| Long Term Debt / Equity (X) | 0.57 | 0.65 | 0.85 | 0.47 | 0.39 |
| Total Debt / Equity (X) | 0.82 | 0.79 | 0.99 | 0.58 | 0.47 |
| Asset Turnover Ratio (%) | 0.26 | 0.27 | 0.30 | 0.12 | 0.17 |
| Current Ratio (X) | 1.14 | 0.98 | 1.45 | 2.19 | 1.81 |
| Quick Ratio (X) | 0.79 | 0.66 | 0.95 | 1.59 | 1.36 |
| Inventory Turnover Ratio (X) | 3.09 | 1.10 | 0.97 | 0.75 | 0.81 |
| Dividend Payout Ratio (NP) (%) | 5.92 | 17.61 | 12.96 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 2.22 | 6.95 | 3.80 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 94.08 | 82.39 | 87.04 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 97.78 | 93.05 | 96.20 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.87 | 4.27 | 6.89 | 32.29 | 33.05 |
| Interest Coverage Ratio (Post Tax) (X) | 2.49 | 2.43 | 3.63 | 17.12 | 16.82 |
| Enterprise Value (Cr.) | 60668.27 | 50669.85 | 44766.88 | 44360.07 | 51477.10 |
| EV / Net Operating Revenue (X) | 3.98 | 3.43 | 4.01 | 5.42 | 7.24 |
| EV / EBITDA (X) | 13.87 | 12.17 | 15.50 | 20.32 | 26.99 |
| MarketCap / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| Retention Ratios (%) | 94.07 | 82.38 | 87.03 | 0.00 | 0.00 |
| Price / BV (X) | 1.89 | 1.60 | 1.39 | 4.76 | 6.51 |
| Price / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| EarningsYield | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.55 (Mar 24) to 8.46, marking a decrease of 0.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 8.46, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.96. This value is within the healthy range. It has increased from 24.58 (Mar 24) to 25.96, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.27. It has decreased from 210.51 (Mar 24) to 180.27, marking a decrease of 30.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.28. It has decreased from 210.52 (Mar 24) to 180.28, marking a decrease of 30.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 127.12. It has increased from 122.90 (Mar 24) to 127.12, marking an increase of 4.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has increased from 34.68 (Mar 24) to 36.44, marking an increase of 1.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.38. This value is within the healthy range. It has increased from 21.62 (Mar 24) to 22.38, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 15.71. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 15.71, marking an increase of 2.31.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 11.51 (Mar 24) to 11.91, marking an increase of 0.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has decreased from 8.52 (Mar 24) to 8.44, marking a decrease of 0.08.
- For PBDIT Margin (%), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from 28.22 (Mar 24) to 28.66, marking an increase of 0.44.
- For PBIT Margin (%), as of Mar 25, the value is 17.60. This value is within the healthy range. It has increased from 17.58 (Mar 24) to 17.60, marking an increase of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 12.36. This value is within the healthy range. It has increased from 10.90 (Mar 24) to 12.36, marking an increase of 1.46.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 9.36.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 8. It has decreased from 6.92 (Mar 24) to 6.63, marking a decrease of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 15. It has decreased from 5.16 (Mar 24) to 4.68, marking a decrease of 0.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.04. This value is below the healthy minimum of 10. It has decreased from 6.37 (Mar 24) to 6.04, marking a decrease of 0.33.
- For Return On Assets (%), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 5. It has decreased from 1.82 (Mar 24) to 1.72, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.57. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.57, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has increased from 0.79 (Mar 24) to 0.82, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.26. It has decreased from 0.27 (Mar 24) to 0.26, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.98 (Mar 24) to 1.14, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.79, marking an increase of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 4. It has increased from 1.10 (Mar 24) to 3.09, marking an increase of 1.99.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.92. This value is below the healthy minimum of 20. It has decreased from 17.61 (Mar 24) to 5.92, marking a decrease of 11.69.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 20. It has decreased from 6.95 (Mar 24) to 2.22, marking a decrease of 4.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.08. This value exceeds the healthy maximum of 70. It has increased from 82.39 (Mar 24) to 94.08, marking an increase of 11.69.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 97.78. This value exceeds the healthy maximum of 70. It has increased from 93.05 (Mar 24) to 97.78, marking an increase of 4.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.87. This value is within the healthy range. It has increased from 4.27 (Mar 24) to 4.87, marking an increase of 0.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.43 (Mar 24) to 2.49, marking an increase of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60,668.27. It has increased from 50,669.85 (Mar 24) to 60,668.27, marking an increase of 9,998.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.98. This value exceeds the healthy maximum of 3. It has increased from 3.43 (Mar 24) to 3.98, marking an increase of 0.55.
- For EV / EBITDA (X), as of Mar 25, the value is 13.87. This value is within the healthy range. It has increased from 12.17 (Mar 24) to 13.87, marking an increase of 1.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For Retention Ratios (%), as of Mar 25, the value is 94.07. This value exceeds the healthy maximum of 70. It has increased from 82.38 (Mar 24) to 94.07, marking an increase of 11.69.
- For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.68% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.79
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 108 (Industry average Stock P/E: 52.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.82
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 20th K.M. Hosur Road, Electronics City, Bengaluru Karnataka 560100 | investor.relations@biocon.com http://www.biocon.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Executive Chairperson |
| Mr. Siddharth Mittal | Managing Director & CEO |
| Prof. Ravi Rasendra Mazumdar | Non Exe.Non Ind.Director |
| Mr. Eric Vivek Mazumdar | Non Exe.Non Ind.Director |
| Mr. Bobby Kanubhai Parikh | Independent Director |
| Mr. Naina Lal Kidwai | Lead Independent Director |
| Ms. Rekha Mehrotra Menon | Independent Director |
| Mr. Nicholas Robert Haggar | Independent Director |
| Mr. Atul Dhawan | Independent Director |
FAQ
What is the intrinsic value of Biocon Ltd?
Biocon Ltd's intrinsic value (as of 09 December 2025) is 823.60 which is 114.48% higher the current market price of 384.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 51,259 Cr. market cap, FY2025-2026 high/low of 425/291, reserves of ₹26,135 Cr, and liabilities of 62,760 Cr.
What is the Market Cap of Biocon Ltd?
The Market Cap of Biocon Ltd is 51,259 Cr..
What is the current Stock Price of Biocon Ltd as on 09 December 2025?
The current stock price of Biocon Ltd as on 09 December 2025 is 384.
What is the High / Low of Biocon Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biocon Ltd stocks is 425/291.
What is the Stock P/E of Biocon Ltd?
The Stock P/E of Biocon Ltd is 108.
What is the Book Value of Biocon Ltd?
The Book Value of Biocon Ltd is 200.
What is the Dividend Yield of Biocon Ltd?
The Dividend Yield of Biocon Ltd is 0.13 %.
What is the ROCE of Biocon Ltd?
The ROCE of Biocon Ltd is 6.25 %.
What is the ROE of Biocon Ltd?
The ROE of Biocon Ltd is 4.76 %.
What is the Face Value of Biocon Ltd?
The Face Value of Biocon Ltd is 5.00.